Antiepileptic drugs in the treatment of rapid-cycling bipolar disorder and bipolar depression

Antiepileptic Drugs to Treat Psychiatric Disorders

Volumn , Issue , 2008, Pages 155-176

  Kemp, David E ^a   Gao, Keming ^a   Calabrese, Joseph R ^a   Muzina, David J ^b  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 66649096867     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.3109/9780849382666-12     Document Type: Chapter

References (86)

1. Dunner DL, Fieve RR. Clinical factors in lithium carbonate prophylaxis failure. Arch Gen Psychiatry 1974; 30(2):229-233.
2. Kupka RW, Luckenbaugh DA, Post RM, et al. Comparison of rapid-cycling and nonrapid-cycling bipolar disorder based on prospective mood ratings in 539 outpatients. Am J Psychiatry 2005; 162(7):1273-1280.
3. Bauer MS, Calabrese J, Dunner DL, et al. Multisite data reanalysis of the validity of rapid cycling as a course modifier for bipolar disorder in DSM-IV. Am J Psychiatry 1994; 151 (4):506-515.
4. Schneck CD, Miklowitz DJ, Calabrese JR, et al. Phenomenology of rapid-cycling bipolar disorder: data from the first 500 participants in the Systematic Treatment Enhancement Program. Am J Psychiatry 2004; 161(10):1902-1908.
5. Maj M, Magliano L, Pirozzi R, et al. Validity of rapid cycling as a course specifier for bipolar disorder. Am J Psychiatry 1994; 151(7):1015-1019.
6. Kupka RW, Luckenbaugh DA, Post RM, et al. Rapid and non-rapid cycling bipolar disorder: a meta-analysis of clinical studies. J Clin Psychiatry 2003; 64(12):1483-1494.
7. Calabrese JR, Shelton MD, Bowden CL, et al. Bipolar rapid cycling: focus on depression as its hallmark. J Clin Psychiatry 2001; 62(suppl 14):34-41.
8. Tondo L, Baldessarini RJ. Rapid cycling in women and men with bipolar manic-depressive disorders. Am J Psychiatry 1998; 155(10):1434-1436.
9. Coryell W, Solomon D, Turvey C, et al. The long-term course of rapid-cycling bipolar disorder. Arch Gen Psychiatry 2003; 60(9):914-920.
10. Gao K, Bilali S, Conroy C. Clinical impacts of comorbid anxiety disorder or substance use disorder on patients with rapid cycling bipolar disorder. Paper presented at: American Psychiatric Association Annual Meeting, May 20-25, 2006, Toronto, Canada.
11. Coryell W, Endicott J, Keller M. Rapidly cycling affective disorder. Demographics, diagnosis, family history, and course. Arch Gen Psychiatry 1992; 49(2):126-131.
12. Kukopulos A, Reginaldi D, Laddomada P, et al. Course of the manic-depressive cycle and changes caused by treatment. Pharmakopsychiatr Neuropsychopharmakol 1980; 13(4):156-167.
13. Maj M, Pirozzi R, Magliano L, et al. Long-term outcome of lithium prophylaxis in bipolar disorder: a 5-year prospective study of 402 patients at a lithium clinic. Am J Psychiatry 1998; 155(1):30-35.
14. Calabrese JR, Woyshville MJ, Kimmel SE, et al. Predictors of valproate response in bipolar rapid cycling. J Clin Psychopharmacol 1993; 13(4):280-283.
15. Post RM, Uhde TW, Roy-Byrne PP, et al. Correlates of antimanic response to carba-mazepine. Psychiatry Res 1987; 21(1):71-83.
16. Joyce PR. Carbamazepine in rapid cycling bipolar affective disorder. Int Clin Psychopharmacol 1988; 3(2):123-129.
17. Okuma T. Effects of carbamazepine and lithium on affective disorders. Neuropsychobiology 1993; 27(3):138-145.
18. Denicoff KD, Smith-Jackson EE, Disney ER, et al. Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder. J Clin Psychiatry 1997; 58(11):470-478.
19. Calabrese JR, Delucchi GA. Spectrum of efficacy of valproate in 55 patients with rapidcycling bipolar disorder. Am J Psychiatry 1990; 147(4):431-434.
20. Calabrese JR, Shelton MD, Rapport DJ, et al. A 20-month, double-blind, maintenance trial of lithium versus divalproex in rapid-cycling bipolar disorder. Am J Psychiatry 2005; 162(11):2152-2161.
21. Bowden CL, Calabrese JR, McElroy SL, et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry 2000; 57(5): 481-489.
22. Di Costanzo E, Schifano F. Lithium alone or in combination with carbamazepine for the treatment of rapid-cycling bipolar affective disorder. Acta Psychiatr Scand 1991; 83 (6):456-459.
23. Suppes T, Brown E, Schuh LM, et al. Rapid versus non-rapid cycling as a predictor of response to olanzapine and divalproex sodium for bipolar mania and maintenance of remission: post hoc analyses of 47-week data. J Affect Disord 2005; 89(1-3):69-77.
24. Smith D, Chadwick D, Baker G, et al. Seizure severity and the quality of life. Epilepsia 1993; 34(suppl 5):S31-S35.
25. Calabrese JR, Bowden CL, McElroy SL, et al. Spectrum of activity of lamotrigine in treatment-refractory bipolar disorder. Am J Psychiatry 1999; 156(7):1019-1023.
26. Calabrese JR, Bowden CL, Sachs GS, et al. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry 1999; 60(2):79-88.
27. Calabrese JR, Fatemi SH, Woyshville MJ. Antidepressant effects of lamotrigine in rapid cycling bipolar disorder. Am J Psychiatry 1996; 153(9):1236.
28. Calabrese JR, Suppes T, Bowden CL, et al. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group. J Clin Psychiatry 2000; 61(11):841-850.
29. Frye MA, Ketter TA, Kimbrell TA, et al. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 2000; 20 (6):607-614.
30. Grunze H, Erfurth A, Marcuse A, et al. Tiagabine appears not to be efficacious in the treatment of acute mania. J Clin Psychiatry 1999; 60(11):759-762.
31. Schaffer LC, Schaffer CB, Howe J. An open case series on the utility of tiagabine as an augmentation in refractory bipolar outpatients. J Affect Disord 2002; 71(1-3):259-263.
32. Suppes T, Chisholm KA, Dhavale D, et al. Tiagabine in treatment refractory bipolar disorder: a clinical case series. Bipolar Disord 2002; 4(5):283-289.
33. Braunig P, Kruger S. Levetiracetam in the treatment of rapid cycling bipolar disorder. J Psychopharmacol 2003; 17(2):239-241.
34. Kaufman KR. Monotherapy treatment of bipolar disorder with levetiracetam. Epilepsy Behav 2004; 5(6):1017-1020.
35. Chen CK, Shiah IS, Yeh CB, et al. Combination treatment of clozapine and topiramate in resistant rapid-cycling bipolar disorder. Clin Neuropharmacol 2005; 28(3):136-138.
36. Kusumakar V, Yatham L, Kutcher S, et al. Preliminary, open-label study of topiramate in rapid-cycling bipolar women. Eur Neuropsychopharmacol 1999; 9:S357.
37. Kushner SF, Khan A, Lane R, et al. Topiramate monotherapy in the management of acute mania: results of four double-blind placebo-controlled trials. Bipolar Disord 2006; 8(1):15-27.
38. McElroy SL, Altshuler LL, Suppes T, et al. Axis I psychiatric comorbidity and its relationship to historical illness variables in 288 patients with bipolar disorder. Am J Psychiatry 2001; 158(3):420-426.
39. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990; 264(19):2511-2518.
40. Brady KT, Lydiard RB. Bipolar affective disorder and substance abuse. J Clin Psychopharmacol 1992; 12(suppl 1):17S-22S.
41. Kemp DE, Gao K, Ganocy SJ, et al. Lithium monotherapy versus the combination of lithium and divalproex for rapid cycling bipolar disorder comorbid with substance abuse or dependence: a 6-month, double-blind, maintenance trial. Neuropsychopharmacology 2006; 31(suppl 1):S106.
42. Wehr TA, Sack DA, Rosenthal NE, et al. Rapid cycling affective disorder: contributing factors and treatment responses in 51 patients. Am J Psychiatry 1988; 145(2):179-184.
43. Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002; 59(6):530-537.
44. Judd LL, Akiskal HS, Schettler PJ, et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry 2003; 60(3):261-269.
45. Post RM, Leverich GS, Nolen WA, et al. A re-evaluation of the role of antidepressants in the treatment of bipolar depression: data from the Stanley Foundation Bipolar Network. Bipolar Disord 2003; 5(6):396-406.
46. Goodwin FK, Jamison K. Manic-Depressive Illness. New York, NY: Oxford University Press, 1990.
47. Chen YW, Dilsaver SC. Lifetime rates of suicide attempts among subjects with bipolar and unipolar disorders relative to subjects with other Axis I disorders. Biol Psychiatry 1996; 39(10):896-899.
48. Fagiolini A, Kupfer DJ, Rucci P, et al. Suicide attempts and ideation in patients with bipolar I disorder. J Clin Psychiatry 2004; 65(4):509-514.
49. Coryell W, Turvey C, Endicott J, et al. Bipolar I affective disorder: predictors of outcome after 15 years. J Affect Disord 1998; 50(2-3):109-116.
50. Post RM, Uhde TW, Roy-Byrne PP, et al. Antidepressant effects of carbamazepine. Am J Psychiatry 1986; 143(1):29-34.
51. Ballenger JC, Post RM. Carbamazepine in manic-depressive illness: a new treatment. Am J Psychiatry 1980; 137(7):782-790.
52. Schatzberg AF, Cole JO, DeBattista C. Manual of Clinical Psychopharmacology. 4th ed. Washington, DC: American Psychiatric Publishing, Inc., 2003.
53. Mattson RH, Cramer JA, Collins JF. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group. N Engl J Med 1992; 327(11):765-771.
54. Joffe RT, Post RM, Uhde TW. Effect of carbamazepine on body weight in affectively ill patients. J Clin Psychiatry 1986; 47(6):313-314.
55. Baruzzi A, Albani F, Riva R. Oxcarbazepine: pharmacokinetic interactions and their clinical relevance. Epilepsia 1994; 35(suppl 3):S14-S19.
56. Wagner KD, Kowatch RA, Emslie GJ, et al. A double-blind, randomized, placebocontrolled trial of oxcarbazepine in the treatment of bipolar disorder in children and adolescents. Am J Psychiatry 2006; 163(7):1179-1186.
57. Winsberg ME, DeGolia SG, Strong CM, et al. Divalproex therapy in medication-naive and mood-stabilizer-naive bipolar II depression. J Affect Disord 2001; 67(1-3):207-212.
58. Davis LL, Bartolucci A, Petty F. Divalproex in the treatment of bipolar depression: a placebo-controlled study. J Affect Disord 2005; 85(3):259-266.
59. Sachs GS, Altshuler LL, Ketter T, et al. Divalproex versus placebo for the treatment of bipolar depression. Poster session presented at: The American College of Neuropsychopharmacology 40th Meeting, December 9-13, 2001, Waikoloa, Hawaii.
60. Ghaemi SN, Gilmer WS, Goldberg JF, et al. Divalproex in the treatment of acute bipolar depression: a preliminary double-blind, placebo-controlled pilot study. J Clin Psychiatry 2007; 68(12):1840-1844.
61. Gyulai L, Bowden CL, McElroy SL, et al. Maintenance efficacy of divalproex in the prevention of bipolar depression. Neuropsychopharmacology 2003; 28(7):1374-1382.
62. Calabrese JR, Huffman RF, White RL, et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disord 2008; 10(2):323-333.
63. Solomon DA, Keitner GI, Miller IW, et al. Course of illness and maintenance treatments for patients with bipolar disorder. J Clin Psychiatry 1995; 56(1):5-13.
64. Perlis RH, Ostacher MJ, Patel JK, et al. Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry 2006; 163(2):217-224.
65. Bowden CL, Calabrese JR, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003; 60(4):392-400.
66. Calabrese JR, Bowden CL, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 2003; 64(9):1013-1024.
67. Prien RF, Caffey EM Jr., Klett CJ. Prophylactic efficacy of lithium carbonate in manic-depressive illness. Report of the Veterans Administration and National Institute of Mental Health collaborative study group. Arch Gen Psychiatry 1973; 28(3):337-341.
68. Calabrese JR, Goldberg JF, Ketter TA, et al. Recurrence in bipolar I disorder: a post hoc analysis excluding relapses in two double-blind maintenance studies. Biol Psychiatry 2006; 59(11):1061-1064.
69. McIntyre RS, Mancini DA, McCann S, et al. Topiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: a preliminary single-blind study. Bipolar Disord 2002; 4(3):207-213.
70. Kanba S, Yagi G, Kamijima K, et al. The first open study of zonisamide, a novel anticonvulsant, shows efficacy in mania. Prog Neuropsychopharmacol Biol Psychiatry 1994; 18(4): 707-715.
71. Anand A, Bukhari L, Jennings SA, et al. A preliminary open-label study of zonisamide treatment for bipolar depression in 10 patients. J Clin Psychiatry 2005; 66(2):195-198.
72. Ghaemi SN, Zablotsky B, Filkowski MM, et al. An open prospective study of zonisamide in acute bipolar depression. J Clin Psychopharmacol 2006; 26(4):385-388.
73. Solomon DA, Ryan CE, Keitner GI, et al. A pilot study of lithium carbonate plus divalproex sodium for the continuation and maintenance treatment of patients with bipolar I disorder. J Clin Psychiatry 1997; 58(3):95-99.
74. Young LT, Joffe RT, Robb JC, et al. Double-blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression. Am J Psychiatry 2000; 157(1):124-126.
75. Schaffer A, Zuker P, Levitt A. Randomized, double-blind pilot trial comparing lamo-trigine versus citalopram for the treatment of bipolar depression. J Affect Disord 2006; 96(1-2):95-99.
76. Ketter TA, Calabrese JR. Stabilization of mood from below versus above baseline in bipolar disorder: a new nomenclature. J Clin Psychiatry 2002; 63(2):146-151.
77. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002; 159(suppl 4):1-50.
78. Keck PE, Perlis RH, Otto MW, et al. The expert consensus guideline series: treatment of bipolar disorder 2004. Postgraduate Med 2004; 1-19.
79. Australian and New Zealand clinical practice guidelines for the treatment of bipolar disorder. Aust N Z J Psychiatry 2004; 38(5):280-305.
80. Calabrese JR, Kasper S, Johnson G, et al. International consensus group on bipolar I depression treatment guidelines. J Clin Psychiatry 2004; 65(4):571-579.
81. Yatham LN, Kennedy SH, O’Donovan C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. Bipolar Disord 2006; 8(6):721-739.
82. Grunze H, Kasper S, Goodwin G, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of bipolar disorders. Part I: Treatment of bipolar depression. World J Biol Psychiatry 2002; 3(3):115-124.
83. Goodwin GM, Young AH. The British Association for Psychopharmacology guidelines for treatment of bipolar disorder: a summary. J Psychopharmacol 2003; 17(4 suppl):3-6.
84. Suppes T, Dennehy EB, Hirschfeld RM, et al. The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J Clin Psychiatry 2005; 66(7):870-886.
85. Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62(6):593-602.
86. Brown EB, McElroy SL, Keck PE, et al. A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. J Clin Psychiatry 2006; 67(7):1025-1033.